Health and Fitness Health and Fitness
Thu, September 22, 2011
Wed, September 21, 2011
Tue, September 20, 2011
Mon, September 19, 2011
Sun, September 18, 2011
Sat, September 17, 2011
Fri, September 16, 2011
Thu, September 15, 2011
Wed, September 14, 2011
Tue, September 13, 2011
Mon, September 12, 2011
Sun, September 11, 2011
Sat, September 10, 2011
Fri, September 9, 2011
Thu, September 8, 2011
Wed, September 7, 2011
Tue, September 6, 2011
Mon, September 5, 2011
Sun, September 4, 2011
Sat, September 3, 2011
Fri, September 2, 2011
Thu, September 1, 2011
Wed, August 31, 2011
Tue, August 30, 2011
[ Tue, Aug 30th 2011 ] - Market Wire
00 a.m. ET
Mon, August 29, 2011
Fri, August 26, 2011
Thu, August 25, 2011
Wed, August 24, 2011
Tue, August 23, 2011

Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011


//health-fitness.news-articles.net/content/2011/ .. ata-recently-presented-at-esc-congress-2011.html
Published in Health and Fitness on Thursday, September 8th 2011 at 17:20 GMT by Market Wire   Print publication without navigation


Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term... -- CARLSBAD, Calif., Sept. 8, 2011 /PRNewswire/ --

Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011

[ ]

CARLSBAD, Calif., Sept. 8, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: [ ISIS ]) announces the following webcast:

What:

Data from Mipomersen's Open-Label Extension Study presented at ESC



When:

Monday, September 12, 2011 at 12:00 p.m. ET / 9:00 a.m. PT



Where:

www.isispharm.com



How:

Live on the Internet.  Simply log onto our Web site listed above.



If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at [ www.isispharm.com ].

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 24 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]


Publication Contributing Sources